Amgen will lay off a quarter of its staff in Cambridge, Mass., and halt all neuroscience research, according to the Boston Business Journal.
The company said in a state Worker Adjustment and Retraining Notification note Nov. 8 that it will cut 149 people at its research facility in Kendall Square. The move comes just a few years after the company expanded to New England from its headquarters in Thousand Oaks, Calif.
Amgen will consolidate the rest of its U.S.-based research work at its Thousand Oaks headquarters and San Francisco offices. A spokesperson did not immediately say what would happen to the rest of the Cambridge-based employees, according to the Boston Business Journal.
The decision comes around the same time the company acquired a 20 percent stake in Chinese drugmaker BeiGene for $2.7 billion.
Read the full article here.